Galena Biopharma, Inc. (GALE) Partners with Dr. Reddy’s Laboratories Ltd. (RDY) to Broaden Geographic Reach and Addressable Patient Population of NeuVax
Today before the opening bell, it was announced that Galena Biopharma and Dr. Reddy’s Laboratories have entered a strategic development and commercialization partnership on NeuVax(TM) (nelipepimut-S) in India.
Dr. Reddy’s is an integrated pharmaceutical company focused on providing affordable and innovative medicines for healthier lives. By partnering with this global pharmaceutical company, Gelena has expanded the depth of its pipeline by increasing the clinical utility of NeuVax in another unmet medical need.
“This partnership with Dr. Reddy’s is consistent with our strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy,” said Mark J. Ahn, Ph.D., President and CEO of Galena Biopharma. “Dr. Reddy’s is a leading pharmaceutical company in India with significant commercialization and development expertise. The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population if approved.”
G V Prasad, Chairman and CEO, Dr. Reddy’s commented, “The partnership accelerates our strong commitment to innovation and efforts to bring newer options for cancer patients. We are delighted with our partnership with Galena Biopharma and we believe NeuVax can be a good potential treatment option to prevent the recurrence of breast and gastric cancer.”
For more information, visit www.galenabiopharma.com or www.drreddys.com
Please read full disclaimers at https://disclaimer.missionir.com